Proteomic profiling of the substantia nigra demonstrates CNDP2 overexpression in Parkinson's disease

Journal of Proteomics

Volumn 75, Issue 15, 2012, Pages 4656-4667

  Licker, Virginie ^a   Côte, Mélanie ^a   Lobrinus, Johannes Alexander ^b   Rodrigo, Neftali ^a   Kövari, Enikö ^b   Hochstrasser, Denis F ^a,b   Turck, Natacha ^a   Sanchez, Jean Charles ^a   Burkhard, Pierre R ^a,b  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

2 D gel electrophoresis; CNDP2; Parkinson's disease; Proteomics; Substantia nigra

Indexed keywords

CELL PROTEIN; CYTOSOLIC NON SPECIFIC DIPEPTIDASE 2; PROTEIN; UNCLASSIFIED DRUG;

AGED; AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; DOPAMINERGIC NERVE CELL; FEMALE; GLIA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; NERVE CELL; NERVE DEGENERATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; DIPEPTIDASES; DOPAMINERGIC NEURONS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; NERVE TISSUE PROTEINS; NEUROGLIA; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEOME; SUBSTANTIA NIGRA;

EID: 84864112048     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.02.032     Document Type: Article

References (37)

1. Forno L.S. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996, 55:259-272.
2. Braak H., Del Tredici K., Rub U., de Vos R.A. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003, 24:197-211.
3. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219:979-980.
4. Marsden C.D. Parkinson's disease. Lancet 1990, 335:948-952.
5. Gasser T., Hardy J., Mizuno Y. Milestones in PD genetics. Mov Disord 2011, 26:1042-1048.
6. McNaught K.S., Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci Lett 2001, 297:191-194.
7. Schapira A.H., Cooper J.M., Dexter D., Clark J.B. Mitochondrial Complex I Deficiency in Parkinson's Disease. J Neurochem 1990, 54:823-827.
8. Lennox G., Lowe J., Landon M., Byrne E.J. Diffuse Lewy body disease: correlative neuropathology using anti-ubiquitin immunocytochemistry. J Neurol Neurosurg Psychiatry 1989, 52:1236-1247.
9. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
10. Jin J., Hulette C., Wang Y., Zhang T. Proteomic identification of a stress protein, mortalin/mthsp70/grp75: relevance to Parkinson disease. Mol Cell Proteomics 2006, 5:1193-1204.
11. Kitsou E., Pan S., Zhang J., Shi M. Identification of proteins in human substantia nigra. Proteomics Clin Appl 2008, 2:776-782.
12. Basso M., Giraudo S., Corpillo D., Bergamasco B. Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics 2004, 4:3943-3952.
13. Werner C., Heyny-von Haussen R., Mall G., Wolf S. Proteome analysis of human substantia nigra in Parkinson's disease. Proteome Sci 2008, 6:8.
14. Crecelius A., Gotz A., Arzberger T., Frohlich T. Assessing quantitative post-mortem changes in the gray matter of the human frontal cortex proteome by 2-D DIGE. Proteomics 2008, 8:1276-1291.
15. Hirsch E.C., Breidert T., Rousselet E., Hunot S. The Role of Glial Reaction and Inflammation in Parkinson's Disease. Ann N Y Acad Sci 2003, 991:214-228.
16. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992, 55:181-184.
17. Sanchez J.C., Chiappe D., Converset V., Hoogland C. The mouse SWISS-2D PAGE database: a tool for proteomics study of diabetes and obesity. Proteomics 2001, 1:136-163.
18. Sanchez J.C., Converset V., Nolan A., Schmid G. Effect of rosiglitazone on the differential expression of diabetes-associated proteins in pancreatic islets of C57Bl/6 lep/lep Mice. Mol Cell Proteomics 2002, 1:509-516.
19. Carrette O., Burkhard P.R., Sanchez J.-C., Hochstrasser D.F. State-of-the-art two-dimensional gel electrophoresis: a key tool of proteomics research. Nat Protoc 2006, 1:812-823.
20. Oakley B.R., Kirsch D.R., Morris N.R. A simplified ultrasensitive silver stain for detecting proteins in polyacrylamide gels. Anal Biochem 1980, 105:361-363.
21. Blum H., Beier H., Gross H.J. Improved silver staining of plant proteins, RNA and DNA in polyacrylamide gels. Electrophoresis 1987, 8:93-99.
22. Burgess J.A., Lescuyer P., Hainard A., Burkhard P.R. Identification of brain cell death associated proteins in human post-mortem cerebrospinal fluid. J Proteome Res 2006, 5:1674-1681.
23. Elias J.E., Gygi S.P. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods 2007, 4:207-214.
24. Carrette O., Burgess J.A., Burkhard P.R., Lang C. Changes of the cortex proteome and Apolipoprotein E in transgenic mouse models of Alzheimer's Disease. J Chromatogr B Analyt Technol Biomed Life Sci 2006, 840:1-9.
25. Otani H., Okumura A., Nagai K., Okumura N. Colocalization of a carnosine-splitting enzyme, tissue carnosinase (CN2)/cytosolic non-specific dipeptidase 2 (CNDP2), with histidine decarboxylase in the tuberomammillary nucleus of the hypothalamus. Neurosci Lett 2008, 445:166-169.
26. Licker V., Burkhard P.R. Neuroproteomics and Parkinson's disease: don't forget human samples. Expert Rev Proteomics 2011, 8:291-294.
27. Singleton A., Gwinn-Hardy K. Parkinson's disease and dementia with Lewy bodies: a difference in dose?. Lancet 2004, 364:1105-1107.
28. Polymeropoulos M., Lavedan C., Leroy E., Ide S. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
29. Braak H., Bohl J.R., Muller C.M., Rub U. Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord 2006, 21:2042-2051.
30. Licker V., Kovari E., Hochstrasser D.F., Burkhard P.R. Proteomics in human Parkinson's disease research. J Proteomics 2009, 73:10-29.
31. Jenner P., Olanow C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996, 47:S161-S170.
32. Friedman A., Arosio P., Finazzi D., Koziorowski D. Ferritin as an important player in neurodegeneration. Parkinsonism Relat Disord 2011, 17:423-430.
33. Vilariño-Güell C., Wider C., Ross O., Dachsel J. VPS35 Mutations in Parkinson Disease. Am J Hum Genet 2011, 89:162-167.
34. Teufel M., Saudek V., Ledig J.P., Bernhardt A. Sequence identification and characterization of human carnosinase and a closely related non-specific dipeptidase. J Biol Chem 2003, 278:6521-6531.
35. Otani H., Okumura N., Hashida-Okumura A., Nagai K. Identification and characterization of a mouse dipeptidase that hydrolyzes L-carnosine. J Biochem 2005, 137:167-175.
36. Kaur H., Kumar C., Junot C., Toledano M.B. Dug1p Is a Cys-Gly peptidase of the gamma-glutamyl cycle of Saccharomyces cerevisiae and represents a novel family of Cys-Gly peptidases. J Biol Chem 2009, 284:14493-14502.
37. Park J.E., Tan H.S., Datta A., Lai R.C. Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol Cell Proteomics 2010, 9:1085-1099.